Bowel Cancer Survivor Develops Rare Scleroderma Crisis
A 61-year-old patient faced sudden organ failure and skin hardening linked to a suspected cancer relapse, despite normal blood markers.
A 61-year-old female cancer survivor developed a life-threatening kidney and skin disorder that doctors linked to the suspected return of her bowel cancer. The rare medical event combined rapidly worsening skin hardening with acute renal failure, highlighting an unusual connection between a growing tumour and the immune system.
Systemic sclerosis, also widely known as scleroderma, is a complex connective tissue disease marked by inflammation, blood vessel damage, and progressive scarring in the skin and internal organs. While the condition usually arises on its own, it can occasionally present as a paraneoplastic syndrome, meaning it is triggered by an underlying malignancy. The case was detailed and published in Oxford Medical Case Reports by Vaishnavi Anu Ganapathy and colleagues.
How a Normal Cancer Test Masked a Dangerous Relapse
Two years prior to this crisis, the patient had undergone surgery to remove a stage IIIC transverse colon adenocarcinoma, a form of bowel cancer, followed by six months of chemotherapy. She remained in remission with regular check-ups, and a blood test in January 2024 showed a normal carcinoembryonic antigen level of 2.0 micrograms per litre, a common tumour marker used to monitor bowel cancer.
Despite the reassuring blood test, the patient arrived at the hospital just one month later with dangerously high blood pressure reading 228 over 121 millimetres of mercury. She reported a two-week history of rapidly advancing skin tightening across her fingers, hands, feet, and lower legs, alongside restricted mouth opening due to perioral skin fibrosis and asymmetric Raynaud’s phenomenon, a condition where blood vessels in the fingers narrow in response to cold.
What Blood Tests and Scans Revealed About the Complication
Laboratory evaluations showed a strongly positive antinuclear antibody test and elevated anti-RNA polymerase III antibodies, which are molecular signatures often tied to aggressive skin thickening and kidney involvement. She also developed a severe blood disorder called thrombotic microangiopathy, where small blood clots form in tiny blood vessels, leading to a low platelet count of 94 times 10 to the ninth power per litre and damaged red blood cells.
Her kidney function deteriorated sharply, with creatinine levels surging from a baseline of 60 to 351 micromoles per litre. Concurrently, a contrast-enhanced computed tomography scan of her abdomen revealed a liver lesion, suspicious lymph nodes, and a blood clot in the inferior vena cava, pointing toward a recurrence of her bowel cancer even though standard tumour markers remained within normal limits.
Why Standard Treatment Options Had to Be Abandoned
Following a multidisciplinary review by oncology, rheumatology, and nephrology specialists, the medical team concluded that the rapid onset of severe scleroderma and kidney failure was a paraneoplastic reaction driven by the suspected cancer relapse. Because her platelet count and kidney filtering rate fell well below safe safety thresholds, active chemotherapy regimens could not be administered without risking life-threatening toxicity.
Immunosuppressive medications typically used for autoimmune diseases were also withheld to prevent accelerating tumour growth. Doctors focused instead on best supportive care, blood transfusions, and intensive blood pressure management using multiple medications, though her condition continued to decline.
Understanding the Broader Medical Takeaways
The patient passed away six months after her initial presentation, with her death attributed to progressive malignancy and scleroderma renal crisis. The authors noted that while cancer-associated scleroderma has been documented in other malignancies, this specific combination involving renal failure and recurrent bowel cancer is exceptionally rare.
This clinical report emphasizes the importance of considering paraneoplastic processes when patients in cancer remission develop sudden, aggressive autoimmune symptoms. Clinicians are reminded that normal tumour markers do not completely rule out recurrence, and rapid multidisciplinary evaluation remains vital when managing complex overlapping diseases.
The research was published in Oxford medical case reports on November 17, 2026.
This article has been fact checked for accuracy, with information verified against reputable sources. Learn more about us and our editorial process.
Last reviewed on .
Article history
- Latest version
Reference(s)
- Ganapathy, Vaishnavi Anu., et al. “Scleroderma renal crisis as first manifestation of presumed colorectal cancer recurrence: a rare paraneoplastic presentation.” Oxford Medical Case Reports, vol. 2026, no. 11, November 17, 2026 Oxford University Press (OUP), doi: 10.1093/omcr/omag214. <https://doi.org/10.1093/omcr/omag214>.
Cite this page:
- Posted by David Anderson